Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal targeted therapy versus irinotecan + temozolomide for relapsed or refractory high-risk neuroblastoma
2011-004062-15Phase 2Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Apr 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasatinib, sirolimus, irinotecan and temozolomide in neuroblastoma (2 arms), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
dasatinibsirolimusirinotecantemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2011-004062-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004062-15.